Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.48 |
| ▸ | FLT1 | P17948 | 11/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310388 | 0.94 | FLT1 (0.48) | EGFRFLT1KDRSYKADORA2B | |
| SCHEMBL6623534 | 0.90 | EGFR (0.51) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6623528 | 0.90 | EGFR (0.51) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6622760 | 0.88 | EGFR (0.55) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6304301 | 0.88 | EGFR (0.49) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6309309 | 0.88 | EGFR (0.49) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6302210 | 0.88 | EGFR (0.49) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6304311 | 0.88 | EGFR (0.49) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6625595 | 0.88 | EGFR (0.51) | EGFRFLT1KDRVCPSYK | |
| SCHEMBL6308553 | 0.88 | EGFR (0.49) | EGFRFLT1KDRVCPSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964961-B2 | Thiophene derivatives useful as anticancer agents | PFIZER INC (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1287001-B1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1287001-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | PFIZER PRODUCTS INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042409-A1 | Thiophene derivatives useful as anticancer agents | TP53, RCC1, CCNA1 | EGFR 532/4885FLT1 733/4885KDR 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.